Back to Search Start Over

MicroRNAs miR-584-5p and miR-425-3p Are Up-Regulated in Plasma of Colorectal Cancer (CRC) Patients: Targeting with Inhibitor Peptide Nucleic Acids Is Associated with Induction of Apoptosis in Colon Cancer Cell Lines.

Authors :
Gasparello J
Papi C
Zurlo M
Gambari L
Manicardi A
Rozzi A
Ferrarini M
Corradini R
Gambari R
Finotti A
Source :
Cancers [Cancers (Basel)] 2022 Dec 25; Vol. 15 (1). Date of Electronic Publication: 2022 Dec 25.
Publication Year :
2022

Abstract

Liquid biopsy has dramatically changed cancer management in the last decade; however, despite the huge number of miRNA signatures available for diagnostic or prognostic purposes, it is still unclear if dysregulated miRNAs in the bloodstream could be used to develop miRNA-based therapeutic approaches. In one author's previous work, nine miRNAs were found to be dysregulated in early-stage colon cancer (CRC) patients by NGS analysis followed by RT-dd-PCR validation. In the present study, the biological effects of the targeting of the most relevant dysregulated miRNAs with anti-miRNA peptide nucleic acids (PNAs) were verified, and their anticancer activity in terms of apoptosis induction was evaluated. Our data demonstrate that targeting bloodstream up-regulated miRNAs using anti-miRNA PNAs leads to the down-regulation of target miRNAs associated with inhibition of the activation of the pro-apoptotic pathway in CRC cellular models. Moreover, very high percentages of apoptotic cells were found when the anti-miRNA PNAs were associated with other pro-apoptotic agents, such as sulforaphane (SFN). The presented data sustain the idea that the targeting of miRNAs up-regulated in the bloodstream with a known role in tumor pathology might be a tool for the design of protocols for anti-tumor therapy based on miRNA-targeting molecules.

Details

Language :
English
ISSN :
2072-6694
Volume :
15
Issue :
1
Database :
MEDLINE
Journal :
Cancers
Publication Type :
Academic Journal
Accession number :
36612125
Full Text :
https://doi.org/10.3390/cancers15010128